Last reviewed · How we verify

NCT06026813: PAS

Pressure Alternating Shoes

Completed NA Results posted Last updated 12 August 2025
What this trial tests

NA trial testing test pressure alternating shoes in Foot Ulcer, Diabetic in 21 participants. Completed in 11 July 2024.

Timeline
7 March 2024
Primary endpoint
11 July 2024
11 July 2024

Quick facts

Lead sponsorUniversity of Texas Southwestern Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment21
Start date7 March 2024
Primary completion11 July 2024
Estimated completion11 July 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Texas Southwestern Medical Center

Who can join

18 and older, any sex, with Foot Ulcer, Diabetic. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Maximum Average Pressure at Baseline With Pressure Alternating Shoes, Right Foot (Before Any Cells Were Offloaded) Primary · Before any cells were offloaded (First 40-seconds of the walk)

Maximum Average pressure values in the plantar regions before offloading during walking. The insole consists of seven air cells that align with specific regions: the big toe (cell 1), the area spanning from the second toe to the fifth toe (cell 2), metatarsal heads (cells 3 and 4), the midfoot (cells 5 and 6), and the heel (cell 7). Measurements were only obtained from the right foot.

Cell 1
GroupValue95% CI
Healthy Controls118.5± 26.4
Patients With Diabetic Neuropathy113.7
Cell 3
GroupValue95% CI
Healthy Controls96.6± 30.2
Patients With Diabetic Neuropathy54.9
Cell 4
GroupValue95% CI
Healthy Controls83.8± 20.0
Patients With Diabetic Neuropathy72.2
Cell 7
GroupValue95% CI
Healthy Controls95.2± 19.0
Patients With Diabetic Neuropathy92.1
Maximum Average Pressure at After Offloading - Diabetic Footwear Equipped With PAS Device Primary · After offloading (approx. 41- 200 seconds walk)

Maximum Average pressure values in the plantar regions after offloading cells during walking. The insole consists of seven air cells that align with specific regions: the big toe (cell 1), the area spanning from the second toe to the fifth toe (cell 2), metatarsal heads (cells 3 and 4), the midfoot (cells 5 and 6), and the heel (cell 7). Measurements were only obtained from the right foot. The results reported represent results for footwear with PAS device.

Cell 1
GroupValue95% CI
Healthy Controls - Footwear With PAS Device97.6± 25.7
Patients With Diabetic Neuropathy - Footwear With PAS Device94.6
Cell 3
GroupValue95% CI
Healthy Controls - Footwear With PAS Device82.5± 26.5
Patients With Diabetic Neuropathy - Footwear With PAS Device48.4
Cell 4
GroupValue95% CI
Healthy Controls - Footwear With PAS Device70.2± 18.1
Patients With Diabetic Neuropathy - Footwear With PAS Device56.6
Cell 7
GroupValue95% CI
Healthy Controls - Footwear With PAS Device83.2± 17.3
Patients With Diabetic Neuropathy - Footwear With PAS Device78.8
Peak Interface Pressure at Baseline (Before Offloading) - Diabetic Footwear Equipped With PAS Device Primary · Baseline (First 40-seconds of the walk)

Peak Interface Pressure values in the plantar regions before offloading during walking. The insole consists of seven air cells that align with specific regions: the big toe (cell 1), the area spanning from the second toe to the fifth toe (cell 2), metatarsal heads (cells 3 and 4), the midfoot (cells 5 and 6), and the heel (cell 7). Measurements were only obtained from the right foot. The results reported represent results for footwear with PAS device.

Cell 1
GroupValue95% CI
Healthy Controls - Footwear With PAS Device146.6± 28.4
Patients With Diabetic Neuropathy - Footwear With PAS Device101.8
Cell 3
GroupValue95% CI
Healthy Controls - Footwear With PAS Device125.1± 37.5
Patients With Diabetic Neuropathy - Footwear With PAS Device51.2
Cell 4
GroupValue95% CI
Healthy Controls - Footwear With PAS Device98.78± 17.3
Patients With Diabetic Neuropathy - Footwear With PAS Device64.2
Cell 7
GroupValue95% CI
Healthy Controls - Footwear With PAS Device107.6± 20.5
Patients With Diabetic Neuropathy - Footwear With PAS Device78.3
Peak Interface Pressure at After Offloading - Diabetic Footwear Equipped With PAS Device Primary · After offloading (approx. 41- 200 seconds walk)

Peak Interface Pressure values in the plantar regions after offloading during walking. The insole consists of seven air cells that align with specific regions: the big toe (cell 1), the area spanning from the second toe to the fifth toe (cell 2), metatarsal heads (cells 3 and 4), the midfoot (cells 5 and 6), and the heel (cell 7). Measurements were only obtained from the right foot. The results reported represent results for footwear with PAS device.

Cell 1
GroupValue95% CI
Healthy Controls - Footwear With PAS Device119.5± 26.32
Patients With Diabetic Neuropathy - Footwear With PAS Device85.6
Cell 3
GroupValue95% CI
Healthy Controls - Footwear With PAS Device105.2± 32.3
Patients With Diabetic Neuropathy - Footwear With PAS Device44.7
Cell 4
GroupValue95% CI
Healthy Controls - Footwear With PAS Device84.21± 16.4
Patients With Diabetic Neuropathy - Footwear With PAS Device51.7
Cell 7
GroupValue95% CI
Healthy Controls - Footwear With PAS Device94.81± 18.8
Patients With Diabetic Neuropathy - Footwear With PAS Device64.1
Max Average Pressure Change Among All Participants - Diabetic Footwear Equipped With PAS Device Primary · Baseline (first 40-second walk), 201 seconds after the intervention ended

Percentage change due to offloading for each participant is measured by dividing the pressure difference between the after offloading and before offloading values divided by the before offloading value. Measurements were only obtained from the right foot. The results reported represent results for footwear with PAS device.

Cell 1
GroupValue95% CI
Healthy Controls - Footwear With PAS Device18.1± 10.4
Patients With Diabetic Neuropathy - Footwear With PAS Device16.7
Cell 3
GroupValue95% CI
Healthy Controls - Footwear With PAS Device14.4± 6.5
Patients With Diabetic Neuropathy - Footwear With PAS Device11.8
Cell 4
GroupValue95% CI
Healthy Controls - Footwear With PAS Device16.4± 6.1
Patients With Diabetic Neuropathy - Footwear With PAS Device21.6
Cell 7
GroupValue95% CI
Healthy Controls - Footwear With PAS Device12.8± 3.4
Patients With Diabetic Neuropathy - Footwear With PAS Device14.4
Peak Pressure Change Among All Participants - Diabetic Footwear Equipped With PAS Device Primary · Baseline (first 40-second walk), 201 seconds after the intervention ended

Peak pressure change due to offloading for each participant is measured by dividing the pressure difference between the peak after offloading and peak before offloading values divided by the peak before offloading value. Measurements were only obtained from the right foot. The results reported represent results for footwear with PAS device.

Cell 1
GroupValue95% CI
Healthy Controls - Footwear With PAS Device18.5± 9.3
Patients With Diabetic Neuropathy - Footwear With PAS Device15.9
Cell 3
GroupValue95% CI
Healthy Controls - Footwear With PAS Device15.93± 6.1
Patients With Diabetic Neuropathy - Footwear With PAS Device12.6
Cell 4
GroupValue95% CI
Healthy Controls - Footwear With PAS Device14.67± 6.8
Patients With Diabetic Neuropathy - Footwear With PAS Device19.5
Cell 7
GroupValue95% CI
Healthy Controls - Footwear With PAS Device11.83± 4.8
Patients With Diabetic Neuropathy - Footwear With PAS Device18.0
Plantar Skin Temperature at Baseline, Right Foot Secondary · Baseline before the intervention (30 minutes after start of visit 1)

Plantar skin temperature measured by a noncontact thermal imaging camera (\*Celcius) before the intervention and without footwear

Right foot
GroupValue95% CI
Healthy Controls29.64± 2.16
Patients With Diabetic Neuropathy34.7
Left foot
GroupValue95% CI
Healthy Controls29.73± 2.07
Patients With Diabetic Neuropathy35
Plantar Skin Temperature Post Intervention, Right Foot Secondary · Post intervention (215 seconds)

Plantar skin temperature measured by a noncontact thermal imaging camera (\*Celcius) post intervention, without footwear

Right foot
GroupValue95% CI
Healthy Controls28.7± 2.04
Patients With Diabetic Neuropathy32.1
Left foot
GroupValue95% CI
Healthy Controls29.35± 1.62
Patients With Diabetic Neuropathy32.2
Tissue Oxygenation (Oxygen Saturation) - for Plantar Lateral Foot Secondary · Baseline (30 minutes after start of visit 1)

Plantar foot tissue oxygenation (Oxygen saturation) is measured by noncontact hyperspectral imaging camera (StO2). Only the right foot was analyzed and without footwear.

GroupValue95% CI
Overall Subjects in Experimental Group67.064.0 – 72.3
Tissue Oxygenation (Oxyhemoglobin and Deoxyhemoglobin ) - for Plantar Lateral Foot Secondary · Baseline (30 minutes after start of visit 1)

Plantar foot tissue oxygenation (Oxyhemoglobin and Deoxyhemoglobin) is measured by noncontact hyperspectral imaging (HSI) camera. Only the right foot was analyzed and without footwear. The accepted measure of oxyhemoglobin and deoxyhemoglobin is arbitrary units (AU). NIR spectrum light passes through skin and is reflected off the blood supplying the tissue. Wavelength dependent light absorption of hemoglobin differs if it is carrying oxygen or not, therefore detecting oxygenated and deoxygenated blood. This was derived from Beer-Lambert Law but would need to be verified by the manufacturer. Th

Oxyhemoglobin
GroupValue95% CI
Overall Subjects in Experimental Group0.500.43 – 0.54
Deoxyhemoglobin
GroupValue95% CI
Overall Subjects in Experimental Group0.240.20 – 0.25
Tissue Oxygenation (Oxygen Saturation) - for Plantar Medial Foot Secondary · Baseline (30 minutes after start of visit 1)

Plantar Medial foot tissue oxygenation (Oxygen saturation) is measured by noncontact hyperspectral imaging camera (StO2). Only the right foot was analyzed and without footwear.

GroupValue95% CI
Overall Subjects in Experimental Group71.066.8 – 72.5
Tissue Oxygenation (Oxyhemoglobin and Deoxyhemoglobin) - for Plantar Medial Foot Secondary · Baseline (30 minutes after start of visit 1)

Plantar medial foot tissue oxygenation (Oxyhemoglobin and Deoxyhemoglobin) is measured by noncontact hyperspectral imaging (HSI) camera. Only the right foot was analyzed. Only the right foot was analyzed and without footwear. The accepted measure of oxyhemoglobin and deoxyhemoglobin is arbitrary units (AU). NIR spectrum light passes through skin and is reflected off the blood supplying the tissue. Wavelength dependent light absorption of hemoglobin differs if it is carrying oxygen or not, therefore detecting oxygenated and deoxygenated blood. This was derived from Beer-Lambert Law but would ne

Oxyhemoglobin
GroupValue95% CI
Overall Subjects in Experimental Group0.460.41 – 0.49
Deoxyhemoglobin
GroupValue95% CI
Overall Subjects in Experimental Group0.190.17 – 0.21

Sponsor's own description

The project is designed to develop and test Pressure Alternating Shoes (PAS), which will periodically off-load certain regions of the foot in order to prevent foot ulcers. An automated dual layer insole compromised of an active pressurized actuator array in combination with a passive compliant layer on top of each actuator to modulate and distribute the plantar surface pressure as desired will be tested. This device will allow us to simultaneously load and offload select areas of the foot using the active layer by inflating and deflating individual actuators using pressurized air. After offloading, the remaining load will be distributed to other areas with inflated actuators. Automatic modulation will be provided through programmable control hardware which will cyclically relieve mechanical loading based on a prescribed duration and frequency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Foot Ulcer, Diabetic

Currently open trials in the same condition.

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06026813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing